Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice

• Published in: Biomedicine & pharmacotherapy Vol. 174; p. 116524
• Main Authors: Ventura-Martínez, Rosa, Ángeles-López, Guadalupe Esther, González-Ugalde, Diana, Domínguez-Páez, Tania, Navarrete-Vázquez, Gabriel, Jaimez, Ruth, Déciga-Campos, Myrna
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.05.2024
• Subjects: Analgesics - pharmacology; Animals; antiallodynic effect; antihyperalgesic effect; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - drug therapy; Diabetic Neuropathies - drug therapy; Dose-Response Relationship, Drug; Gabapentin - pharmacology; Haloperidol - pharmacology; Hyperalgesia - drug therapy; LMH-2; Male; Mice; Molecular Docking Simulation; Neuralgia - drug therapy; neuropathic pain; Receptors, sigma - antagonists & inhibitors; Receptors, sigma - metabolism; Sigma-1 Receptor; Streptozocin; SS; NA+STZ; D2R; TCs; S.c; I.p; σ1R; sigma-1 receptor; PRAM; antiallodynic effect; S.E.M; AUC; antihyperalgesic effect; HAL; N.s; neuropathic pain; Au; GBP; ANOVA; VEH; Ki; LMH-2

This study evaluates the antiallodynic and antihyperalgesic effects of LMH-2, a new haloperidol (HAL) analog that acts as sigma-1 receptor (σ1 R) antagonist, in diabetic mice using a model of neuropathic pain induced by chronic hyperglycemia. Additionally, we compared its effects with those of HAL....